The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Diagnosis & Disease Information
Combined Modality Therapy May Improve Overall Survival in Pediatric Hodgkin Lymphoma
Treatment for early-stage pediatric HL can include chemotherapy with or without radiotherapy, although use of radiotherapy is waning.
Consensus Panel on Maintenance Therapies Following Autologous Hematopoietic Cell Transplantation in Lymphoma
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Clinicians Face Uncertainties in Treating Older Patients With Hodgkin Lymphoma
A lack of research focusing primarily on older patients with Hodgkin lymphoma has led to an unmet need for effective, less toxic treatment in this population.
Long-Term Survival in Patients With Advanced Stage Hodgkin Lymphoma
Researchers analyzed long-term follow-up data from 2 clinical trials conducted by the German Hodgkin Study Group.
Conflicting Findings of EBV-Biomarker Use in HIV-Related Lymphomas
Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.
Symptomatic Osteonecrosis as a Treatment Complication in Hodgkin Lymphoma
Though osteonecrosis has been previously studied in childhood ALL, it has not been evaluated as a side effect of treatment for Hodgkin lymphoma.
Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.
Preliminary Topline Results for Tislelizumab in Classical Hodgkin Lymphoma
A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.
- Loading...
Loading...
Loading... 
Loading...